Should we use risk selection tests for HPV 16 and/or 18 positive
cases: comparison of p16/Ki67 and cytology
Karolina Mazurec1, Martyna
Trzeszcz1,2*, Maciej Mazurec1,
Joanna Streb3, Agnieszka Halon4,
Robert Jach5
1 Corfamed Woman’s Health Center, Kluczborska 37,
50-322 Wroclaw, Poland;
carlos.mazurec@icloud.com
(K.M.);
m.mazurec@corfamed.pl
(M.M.)2 Division of Pathology and Clinical Cytology,
University Hospital in Wroclaw, Borowska 213, 50-556 Wroclaw, Poland;
m.trzeszcz@corfamed.pl
(M.T.)3 Department of Oncology, Jagiellonian University
Medical College, Kopernika 50, 31-501 Krakow, Poland;
joanna.streb@uj.edu.pl
(J.S.)4 Department of Clinical and Experimental Pathology,
Division of Clinical Pathology, Wroclaw Medical University, Borowska
213, 50-556 Wroclaw, Poland;
agnieszka.halon@umed.wroc.pl
(A.H.)5 Division of Gynecologic Endocrinology, Jagiellonian
University Medical College, Kopernika 23, 31-501 Krakow, Poland;
jach@cm-uj.krakow.pl
(R.J.)
*Corresponding author
Correspondence to: Martyna Trzeszcz, MD, PhD, Division of
Pathology and Clinical Cytology, University Hospital in Wroclaw,
Borowska 213, 50-556 Wroclaw, Poland;
m.trzeszcz@corfamed.pl
(M.T.); +48508646805
Conflicts of Interest : Robert Jach has given a lecture
sponsored by the Roche company. The other authors declare no conflict of
interest.
Funding : This research received no external funding.
Ethics Statement : The study was conducted in accordance with
the Declaration of Helsinki and approved by the Ethics Committee of the
Jagiellonian University (opinion ID 118.6120.36.2023).
Shortened title : Should we use triage tests for HPV 16/18+
cases?